血浆NCAM/ABCA1双标外泌体内Aβ42和microRNA-388-5p在阿尔茨海默病早期诊断中的价值

凌四海 支杨 李莹 陈霞利 刘辰庚

凌四海, 支杨, 李莹, 陈霞利, 刘辰庚. 血浆NCAM/ABCA1双标外泌体内Aβ42和microRNA-388-5p在阿尔茨海默病早期诊断中的价值[J]. 疾病监测, 2022, 37(6): 821-825. doi: 10.3784/jbjc.202201190005
引用本文: 凌四海, 支杨, 李莹, 陈霞利, 刘辰庚. 血浆NCAM/ABCA1双标外泌体内Aβ42和microRNA-388-5p在阿尔茨海默病早期诊断中的价值[J]. 疾病监测, 2022, 37(6): 821-825. doi: 10.3784/jbjc.202201190005
Ling Sihai, Zhi Yang, Li Ying, Chen Xiali, Liu Chengeng. Value of plasma NCAM/ABCA1 double-labeled exosomal Aβ42 and microRNA-388-5p in early diagnosis of Alzheimer's disease[J]. Disease Surveillance, 2022, 37(6): 821-825. doi: 10.3784/jbjc.202201190005
Citation: Ling Sihai, Zhi Yang, Li Ying, Chen Xiali, Liu Chengeng. Value of plasma NCAM/ABCA1 double-labeled exosomal Aβ42 and microRNA-388-5p in early diagnosis of Alzheimer's disease[J]. Disease Surveillance, 2022, 37(6): 821-825. doi: 10.3784/jbjc.202201190005

血浆NCAM/ABCA1双标外泌体内Aβ42和microRNA-388-5p在阿尔茨海默病早期诊断中的价值

doi: 10.3784/jbjc.202201190005
基金项目: 北京市属医院科研培育计划(No. PX2022077);国家自然科学基金(No. 81401734);国家重点研发计划(No. 2019YFF0216502)
详细信息
    作者简介:

    凌四海,女,湖南省长沙市人,硕士,副主任技师,主要从事疾病监测和诊断标志物筛选工作,Email: lingsihai@mail.ccmu.edu.cn

    通讯作者:

    刘辰庚, Tel:010–58303217,Email:brown117@163.com

  • 中图分类号: R211; R446.1

Value of plasma NCAM/ABCA1 double-labeled exosomal Aβ42 and microRNA-388-5p in early diagnosis of Alzheimer's disease

Funds: This study was supported by the fund for Beijing Municipal Administration of Hospitals Incubating Program (No. PX2022077), the National Natural Science Foundation of China (No. 81401734) and the fund for National Key Research and Development Program of China (No. 2019YFF0216502)
  • 摘要:   目的  检测神经细胞黏附分子(NCAM)和三磷酸腺苷(ATP)结合盒转运体A1(ABCA1)双标记外泌体内Aβ42和microRNA-388-5p(miR-388-5p),并分析其在阿尔茨海默病(AD)早期诊断中的潜在价值。  方法  检测67例主观认知下降(SCD)、65例遗忘型轻度认知障碍(aMCI)、68例痴呆期阿尔茨海默病(DAT)患者、60例健康对照组受试者及60例血管性痴呆(VaD)的疾病对照组患者的血浆NCAM/ABCA1外泌体Aβ42和miR-388-5p水平,分析各指标间的相关性及其对疾病发展阶段的诊断效能。  结果  SCD、aMCI和DAT受试者血浆NCAM/ABCA1双标外泌体Aβ42水平均显著高于VaD和健康对照组受试者(P<0.05);SCD、aMCI和DAT受试者血浆NCAM/ABCA1双标外泌体miR-388-5p含量均显著低于VaD及对照组受试者(P<0.05)。 血浆NCAM/ABCA1双标外泌体内Aβ42对SCD、aMCI和DAT诊断的敏感度和特异度均高于miR-388-5p。  结论  本研究提示NCAM/ABCA1双标外泌体中Aβ42和miR-388-5p可作为aMCI和SCD诊断或预警的候选标志物,但尚需纵向多中心研究以进一步证实。
  • 图  1  受试者工作特征曲线

    注: SCD、aMCI和DAT患者血浆总Aβ42(A)和miR-388-5p(B)相对健康对照组的ROC曲线; SCD、aMCI和DAT患者外周血NCAM/ABCA1双标外泌体内Aβ42(C)和miR-388-5p(D)相对健康对照组的ROC曲线。SCD. 主观认知下降;aMCI. 遗忘型轻度认知障碍;DAT. 痴呆期阿尔茨海默病;ROC.受试者工作特征

    Figure  1.  ROC curve

    表  1  不同受试组总Aβ42和双标外泌体内Aβ42的吸光度

    Table  1.   Total Aβ42 and Aβ42 absorbance in double-labeled exosomes in different groups

    分组总Aβ42双标外泌体内Aβ42P
    与DAT比较与aMCI比较与SCD比较与VaD比较
    对照组3.12±0.591.03±0.280.003/<0.0010.028/<0.0010.092/0.0190.139/0.088
    VaD3.09±0.611.08±0.310.007/<0.0010.039/<0.0010.188/0.0651.000/1.000
    SCD2.93±0.561.36±0.330.013/<0.0010.072/0.0081.000/1.0000.188/0.065
    aMCI2.81±0.432.01±0.350.009/<0.0011.000/1.0000.072/0.0080.039/<0.001
    DAT2.56±0.383.09±0.431.000/1.0000.009/<0.0010.013/<0.0010.007/<0.001
    注:P值分别表示为总Aβ42/双标外泌体内Aβ42与不同受试组的两两比较。VaD. 血管性痴呆;SCD. 主观认知下降;aMCI. 遗忘型轻度认知障碍;DAT. 痴呆期阿尔茨海默病;P值栏数据表示为“总Aβ42组间比较的P值/双标外泌体内Aβ42组间比较的P值”
    下载: 导出CSV

    表  2  不同受试组总MiR-388-5p和双标外泌体内MiR-388-5p的水平

    Table  2.   Total MiR-388-5p and double-labeled exosome MiR-388-5p levels in different groups

    分组总miR-388-5p双标外泌体内miR-388-5pP
    与DAT比较与aMCI比较与SCD比较与VaD比较
    对照组1.51±0.352.93±0.490.002/<0.0010.033/<0.0010.102/0.0250.156/0.093
    VaD1.55±0.430.82±0.430.013/<0.0010.049/<0.0010.233/0.0361.000/1.000
    SCD1.35±0.292.38±0.350.025/<0.0010.093/0.0011.000/1.0000.233/0.036
    aMCI1.22±0.231.33±0.200.002/<0.0011.000/1.0000.093/0.0010.033/<0.001
    DAT0.77±0.110.81±0.131.000/1.0000.002/<0.0010.025/<0.0010.013/<0.001
    注:P值分别表示总miR-388-5p /双标外泌体内miR-388-5p与不同受试组的两两比较。VaD.血管性痴呆;SCD. 主观认知下降;aMCI. 遗忘型轻度认知障碍;DAT. 痴呆期阿尔茨海默病;P值栏数据表示为“总miR-388-5p组间比较的P值/双标外泌体内miR-388-5p组间比较的P值”
    下载: 导出CSV

    表  3  各组内Aβ42与miR-388-5p相关性分析

    Table  3.   Correlation analysis between Aβ42 and miR-388-5p in each group

    Aβ42与
    miR-388-5p来源
    对照组VaDSCDaMCIDAT总体分析
    rPrPrPrPrPrP
    血浆总量 0.491 0.003 0.438 0.017 0.382 0.035 0.417 0.011 0.450 0.009 0.423 0.021
    血浆双标外泌体−0.634<0.001−0.672<0.001−0.528<0.001−0.692<0.001−0.685<0.001−0.653<0.001
    注:P值表示为相关性分析的统计结果。VaD. 血管性痴呆;SCD. 主观认知下降;aMCI. 遗忘型轻度认知障碍;DAT. 痴呆期阿尔茨海默病
    下载: 导出CSV

    表  4  受试者工作特征曲线和诊断效能分析结果

    Table  4.   Receiver operating characteristic curve and diagnostic performance analysis results

    分组来源项目曲线下
    面积
    标准误95%置信区间截断值P敏感度(%)χ2特异度(%)χ2
    下限上限
    SCD血浆总体Aβ420.5250.0190.5060.5441.29 0.002 62.538.969 66.337.592
    miR-388-5p0.5290.0290.5000.5582.930.00161.563.3
    外泌体内Aβ420.6830.0290.6540.7121.020.00673.5a48.956 71.4 a51.015
    miR-388-5p0.6150.0200.5950.6352.77<0.00167.366.3
    aMCI血浆总体Aβ420.6770.0210.6560.6981.980.00568.636.95768.337.569
    miR-388-5p0.6210.0200.6010.6411.850.01767.267.5
    外泌体内Aβ420.7390.0310.7010.7701.770.00372.339.87171.936.755
    miR-388-5p0.6620.0230.6390.6851.65<0.00169.570.3
    DAT血浆总体Aβ420.7710.0300.7410.8013.010.00370.238.21570.137.567
    miR-388-5p0.7090.0280.6810.7371.230.00268.869.5
    外泌体内Aβ420.8150.0350.7800.8502.69<0.001 79.3 a45.639 81.3 a47.051
    miR-388-5p0.7690.0280.7010.7570.97<0.00173.175.7
    注:a. 与同组的miR-388-5p相比P<0.05。SCD. 主观认知下降;aMCI. 遗忘型轻度认知障碍;DAT. 痴呆期阿尔茨海默病
    下载: 导出CSV
  • [1] Cortes-Canteli M, Iadecola C. Alzheimer's disease and vascular aging: JACC focus seminar[J]. J Am Coll Cardiol, 2020, 75(8): 942–951. DOI:  10.1016/j.jacc.2019.10.062.
    [2] Brent RJ. Behavioral versus biological definitions of dementia symptoms: recognizing that worthwhile interventions already exist[J]. OBM Geriat, 2019, 3(4): 10. DOI:  10.21926/obm.geriatr.1904079.
    [3] Liu CG, Zhao Y, Lu Y, et al. ABCA1-labeled exosomes in serum contain higher MicroRNA-193b levels in Alzheimer's disease[J]. Biomed Res Int, 2021, 2021: 5450397. DOI:  10.1155/2021/5450397.
    [4] Das Nair R, Bradshaw LE, Carpenter H, et al. A group memory rehabilitation programme for people with traumatic brain injuries: the ReMemBrIn RCT[J]. Health Technol Assess, 2019, 23(16): 1–194. DOI:  10.3310/hta23160.
    [5] Zhang S, Huang SY, An XB, et al. Medical histories of control subjects influence the biomarker potential of plasma Aβ in Alzheimer's disease: a meta-analysis[J]. J Mol Neurosci, 2020, 70(6): 861–870. DOI: 10.1007/s12031−020−01510−1.
    [6] Clare L, Kudlicka A, Oyebode JR, et al. Goal-oriented cognitive rehabilitation for early-stage Alzheimer's and related dementias: the GREAT RCT[J]. Health Technol Assess, 2019, 23(10): 1–242. DOI:  10.3310/hta23100.
    [7] Jia LF, Quan MN, Fu Y, et al. Dementia in China: epidemiology, clinical management, and research advances[J]. Lancet Neurol, 2020, 19(1): 81–92. DOI: 10.1016/S1474−4422(19)30290−X.
    [8] Li Y, Meng S, Di W, et al. Amyloid-β protein and MicroRNA-384 in NCAM-Labeled exosomes from peripheral blood are potential diagnostic markers for Alzheimer's disease[J]. CNS Neurosci Ther, 2022. DOI:  10.1111/cns.13846.
    [9] Jia LF, Qiu QQ, Zhang H, et al. Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid[J]. Alzheimers Dement, 2019, 15(8): 1071–1080. DOI:  10.1016/j.jalz.2019.05.002.
    [10] Dehghani R, Rahmani F, Rezaei N. MicroRNA in Alzheimer's disease revisited: implications for major neuropathological mechanisms[J]. Rev Neurosci, 2018, 29(2): 161–182. DOI: 10.1515/revneuro−2017−0042.
    [11] Putteeraj M, Fairuz YM, Teoh SL. MicroRNA Dysregulation in Alzheimer's Disease[J]. CNS Neurol Disord Drug Targets, 2017, 16(9): 1000–1009. DOI:  10.2174/1871527316666170807142311.
    [12] Theillet G, Martinez J, Steinbrugger C, et al. Comparative study of chikungunya virus-like particles and pseudotyped-particles used for serological detection of specific immunoglobulin M[J]. Virology, 2019, 529: 195–204. DOI:  10.1016/j.virol.2019.01.027.
    [13] Deng H, Sun C, Sun YX, et al. Lipid, protein, and MicroRNA composition within mesenchymal stem cell-derived exosomes[J]. Cell Reprogram, 2018, 20(3): 178–186. DOI:  10.1089/cell.2017.0047.
    [14] Juźwik CA, Drake SS, Zhang Y, et al. microRNA dysregulation in neurodegenerative diseases: A systematic review[J]. Prog Neurobiol, 2019, 182: 101664. DOI:  10.1016/j.pneurobio.2019.101664.
  • 加载中
图(1) / 表(4)
计量
  • 文章访问数:  44
  • HTML全文浏览量:  26
  • PDF下载量:  3
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-01-19
  • 网络出版日期:  2022-05-27
  • 刊出日期:  2022-07-14

目录

    /

    返回文章
    返回

    在线交流

    防诈骗公告

    近期有不法分子以本刊编辑身份添加作者微信,请务必提高警惕!本刊关于稿件的一切事项通知均采用编辑部唯一邮箱(jbjc@icdc.cn)和座机(010-58900732)联系作者,且在录用稿件后仅收取版面费,无其他任何名目费用(如审稿费和加急费等),非编辑部邮箱发送的本刊收费用通知等均为诈骗,不要随意汇入款项!如有可疑及时致电编辑部核实确认!